Oppenheimer Asset Management Inc. Cuts Stock Position in Certara, Inc. (NASDAQ:CERT)

Oppenheimer Asset Management Inc. lessened its stake in shares of Certara, Inc. (NASDAQ:CERT) by 16.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 177,280 shares of the company’s stock after selling 33,944 shares during the quarter. Oppenheimer Asset Management Inc. owned about 0.11% of Certara worth $1,888,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Venturi Wealth Management LLC raised its stake in shares of Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after purchasing an additional 2,509 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after purchasing an additional 822 shares during the last quarter. KBC Group NV raised its stake in shares of Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Certara by 442.2% during the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock worth $90,000 after purchasing an additional 6,868 shares during the last quarter. Finally, Moloney Securities Asset Management LLC purchased a new stake in shares of Certara during the fourth quarter worth approximately $128,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Stock Down 3.4 %

Certara stock opened at $11.98 on Monday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -59.90, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. Certara, Inc. has a fifty-two week low of $9.41 and a fifty-two week high of $19.87. The stock’s fifty day moving average is $12.45 and its two-hundred day moving average is $11.63.

Wall Street Analyst Weigh In

CERT has been the subject of several analyst reports. Robert W. Baird cut their price target on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. TD Cowen initiated coverage on Certara in a report on Thursday. They set a “buy” rating and a $16.00 price objective on the stock. Stephens reaffirmed an “overweight” rating and set a $17.00 price objective on shares of Certara in a report on Thursday. Barclays upped their price objective on Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday. Finally, William Blair reaffirmed a “market perform” rating on shares of Certara in a report on Thursday. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Certara currently has a consensus rating of “Moderate Buy” and an average target price of $15.83.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.